A comparison was made between two different methods of reproductive management in the dairy cow. One protocol administered prostaglandin to open cows weekly; the other administered prostaglandin to open cows with a corpus luteum identified by rectal palpation. Survival analysis was used to analyze the data. Cows receiving weekly doses of prostaglandin had a 30% higher pregnancy rate (number of pregnancies per time) than the cows receiving prostaglandin based on rectal palpation of a corpus luteum. The average number of days to first insemination was shorter in cows given prostaglandin weekly.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.3168/jds.S0022-0302(92)78033-3 | DOI Listing |
World J Stem Cells
January 2025
Department of Anatomy and Cell Biology, College of Medicine, Chung-Ang University, Seoul 06974, South Korea.
Background: Human mesenchymal stromal cells (MSCs) possess regenerative potential due to pluripotency and paracrine functions. However, their stemness and immunomodulatory capabilities are sub-optimal in conventional two-dimensional (2D) culture.
Aim: To enhance the efficiency and therapeutic efficacy of MSCs, an -like 3D culture condition was applied.
Prostaglandins Other Lipid Mediat
January 2025
Department of Pharmacology, Vocational School of Health Services, Adıyaman University, Adıyaman, Turkey.
Cardiovascular complications resulting from cisplatin (CS) are a significant factor that can disrupt the treatment plan associated with this chemotherapy. This information led us to investigate the effectiveness of lutein (LT), which has antioxidant effects, in preventing CS-induced cardiotoxic effects. After 28 rats were randomly divided into four equal groups, saline (1 ml/day) was administered to the control group, LT (100 mg/kg/day) to the LT group, CS (10 mg/kg) to the CS group, and active agents in the LT and CS groups were administered to the CS + LT group in the same dose and manner.
View Article and Find Full Text PDFFront Pharmacol
January 2025
Institute of Pharmacology and the Gaston H. Glock Research Laboratories for Exploratory Drug Development, Centre of Physiology and Pharmacology, Medical University of Vienna, Vienna, Austria.
Objective: The expanding field of hematopoietic cell transplantation (HCT) for non-malignant diseases, including those amenable to gene therapy or gene editing, faces challenges due to limited donor availability and the toxicity associated with cell collection methods. Umbilical cord blood (CB) represents a readily accessible source of hematopoietic stem and progenitor cells (HSPCs); however, the cell dose obtainable from a single cord blood unit is frequently insufficient. This limitation can be addressed by enhancing the potency of HSPCs, specifically their capacity to reconstitute hematopoiesis.
View Article and Find Full Text PDFClin Pharmacol Drug Dev
January 2025
Taiho Pharmaceutical Co., Ltd., Tokyo, Japan.
Pizuglanstat is a novel hematopoietic prostaglandin D synthase inhibitor and investigational treatment for Duchenne muscular dystrophy. This Phase 1 mass balance study aimed to characterize the absorption, metabolism, and excretion of carbon-14 (C)-labeled pizuglanstat in healthy adults (ClinicalTrials.gov, NCT04825431).
View Article and Find Full Text PDFBackground: Prostaglandin E (PGE) in the rostral ventrolateral medulla (RVLM) has been recognized as a pivotal pressor substance in hypertension, yet understanding of its effects and origins in the RVLM remains largely elusive. This study aimed to elucidate the pivotal enzymes and molecular mechanisms underlying PGE synthesis induced by central Ang II (angiotensin II) and its implications in the heightened oxidative stress and sympathetic outflow in hypertension.
Methods And Results: RVLM microinjections of PGE and Tempol were administered in Wistar-Kyoto rats.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!